未名医药(002581) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥35,329,856.70, a decrease of 57.84% compared to ¥83,804,783.29 in the same period last year[5] - The net loss attributable to shareholders was ¥36,850,397.17, representing a 33.01% increase from a loss of ¥27,704,081.15 in the previous year[5] - The net cash flow from operating activities was -¥58,614,130.67, a significant decline of 285.59% compared to -¥15,200,975.67 in the same period last year[5] - The basic and diluted earnings per share were both -¥0.0559, a decrease of 33.10% from -¥0.0420 in the previous year[5] - The company reported a 57.84% decrease in operating income primarily due to product recalls[13] - Total operating revenue for the current period is CNY 35,329,856.70, a decrease of 57.8% compared to CNY 83,804,783.29 in the previous period[28] - Net profit for the current period is a loss of CNY 49,818,616.89, compared to a loss of CNY 27,055,340.81 in the previous period, indicating a worsening financial performance[29] - The net profit attributable to the parent company was -36,850,397.17 yuan, compared to -27,704,081.15 yuan in the previous period, indicating a decline[30] - The total comprehensive income amounted to -49,818,616.89 yuan, compared to -27,055,340.81 yuan in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,167,843,796.67, down 1.28% from ¥2,195,918,588.20 at the end of the previous year[5] - The balance of other receivables increased by 97.55% compared to the beginning of the year, mainly due to prepayments made for the industrial park[8] - The balance of contract liabilities increased by 160.57% compared to the beginning of the year, attributed to pre-received contract payments[10] - Total current assets decreased to CNY 729,876,009.75 from CNY 747,007,338.19, a decline of 2.3%[26] - Total liabilities increased to CNY 190,692,131.12 from CNY 173,612,003.09, an increase of 9.9%[27] - Long-term equity investments slightly decreased to CNY 1,048,822,473.33 from CNY 1,055,730,183.04, a decrease of 0.7%[26] Cash Flow - The company reported a decrease in cash and cash equivalents from RMB 506,403,730.00 at the beginning of the period to RMB 445,010,515.55 at the end of the period[25] - The company’s cash flow management remains a focus, with a significant reduction in cash reserves noted[25] - Cash inflows from operating activities totaled 67,021,948.27 yuan, down from 103,266,237.28 yuan in the previous period[32] - The net cash flow from operating activities was -58,614,130.67 yuan, compared to -15,200,975.67 yuan in the previous period[32] - The cash and cash equivalents at the end of the period were 442,764,542.95 yuan, down from 504,337,388.39 yuan at the beginning of the period[33] - The net cash increase in cash and cash equivalents was -61,572,845.44 yuan, compared to an increase of 63,453,004.06 yuan in the previous period[32] Expenses and Costs - Total operating costs for the current period amount to CNY 79,830,761.69, down 25.0% from CNY 106,361,412.35 in the previous period[29] - Research and development expenses for the current period were CNY 4,880,913.96, down 21.4% from CNY 6,208,293.77 in the previous period[29] - The company reported a financial cost of CNY -803,773.97, indicating a reduction in financial expenses compared to CNY -277,387.95 in the previous period[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,037[18] - The company’s top 10 unrestricted shareholders include Shenzhen Yilian Technology Co., Ltd. with 25,204,000 shares, accounting for 3.82%[19] - The company has not disclosed any changes in the participation of major shareholders in margin trading and securities lending activities[19] - The company has not identified any related party relationships or concerted actions among the top 10 shareholders[19] Corporate Actions and Agreements - The company approved a capital increase of RMB 290 million for its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., raising its registered capital to RMB 300 million[22] - The company signed a clinical trial technical service agreement for the Phase III clinical trial of recombinant human nerve growth factor eye drops with Tianjin Happy Life Technology Co., Ltd.[21] - The company plans to sign a general contracting agreement for the cleanroom and electromechanical project of the Shandong Weiming Biomedical Industrial Park with Shandong Zhongda Engineering Technology Co., Ltd.[23] - The company’s wholly-owned subsidiary will procure necessary systems and materials for the production workshop of recombinant human nerve growth factor eye drops from Jiangsu Suhao Innovation Technology Group Co., Ltd.[24] Compliance and Reporting - The company did not undergo an audit for the first quarter report[34] - The report was issued by the Board of Directors on April 28, 2025[35]